MedDataX Logo

Study Evaluating the Addition of Sildenafil to Bosentan Therapy in Pulmonary Arterial Hypertension

NCT ID: NCT00780728

Last Updated: 2009-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will examine the effects of add-on sildenafil to bosentan monotherapy in patients with Pulmonary Arterial Hypertension. Patients on bosentan monotherapy will be followed every 6 months to assess if they have met the pre-defined treatment goals. If a patient fails to achieve these treatment goals or fails to maintain them, sildenafil will be added to their existing bosentan monotherapy. Patients will be assessed 6 months after start of combination therapy for changes in 6MWT, Borg dyspnea scale, WHO functional class, quality of life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

First-line Bosentan and Sildenafil Combination Therapy for Pulmonary Arterial Hypertension

NCT01247116

Hypertension, Pulmonary
COMPLETED

Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)

NCT00303459

Pulmonary Arterial Hypertension
COMPLETED PHASE4

Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients

NCT01712997

Pulmonary Arterial Hypertension
UNKNOWN PHASE3

Efficacy and Safety of Upfront Combination of ΒΟsentan and ΤΑdalafil in Pulmonary Arterial Hypertension

NCT03139084

Pulmonary Hypertension
WITHDRAWN

Combination Therapy in Pulmonary Arterial Hypertension

NCT00433329

Pulmonary Arterial Hypertension
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension, Pulmonary

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sildenafil

Group Type ACTIVE_COMPARATOR

Sildenafil

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sildenafil

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion \& Exclusion Criteria
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Health Network, Toronto

OTHER

Sponsor Role lead

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UHNOHI

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension
NCT00313222 COMPLETED PHASE3
Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia
NCT01449253 UNKNOWN PHASE4
Efficacy and Safety of Bosentan in Sickle Cell Disease (SCD) Patients With Pulmonary Arterial Hypertension (PAH)
NCT00310830 TERMINATED PHASE3
Goal Oriented Strategy to Preserve Ejection Fraction Trial
NCT03236818 UNKNOWN PHASE4
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
NCT00091715 COMPLETED PHASE3
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
NCT00302211 TERMINATED PHASE3
Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH
NCT02304198 COMPLETED PHASE2/PHASE3
Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)
NCT00120380 TERMINATED PHASE4
Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE
NCT01827059 UNKNOWN PHASE2
Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
NCT00452218 COMPLETED PHASE1
Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension
NCT01548950 COMPLETED NA
Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension
NCT01330108 COMPLETED PHASE4
Long Acting Phosphodiesterase 5 Inhibitors as Add-on Therapy for Patients With Pulmonary Hypertension Treated With Prostanoids.
NCT00705588 UNKNOWN PHASE4
Bosentan in Children With Pulmonary Arterial Hypertension Extension Study
NCT00319020 COMPLETED PHASE3
Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants
NCT01392469 COMPLETED PHASE3
Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension
NCT04039464 COMPLETED PHASE3
A Study to Evaluate the Use of Bosentan in Patients With Exercise Induced Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
NCT00864201 UNKNOWN PHASE3
Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension
NCT00709098 COMPLETED PHASE3
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
NCT07073820 RECRUITING PHASE2
Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.
NCT01800292 COMPLETED PHASE4
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
NCT00741819 COMPLETED PHASE4
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
NCT07218029 RECRUITING PHASE3
Combined Use of Angiography, Optical Coherence Tomography and Intravascular Ultrasound in Evaluation of Pulmonary Vascular Structure and Function in Patients With Pulmonary Arterial Hypertension Treated With Oral Bosentan
NCT01508780 WITHDRAWN PHASE4
A Study of Patients Having Pulmonary Hypertension Associated With Sickle Cell Disease and Completing an ASSET Study
NCT00360087 TERMINATED PHASE3
A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension
NCT03738150 COMPLETED PHASE2